Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.
Type:
Grant
Filed:
March 20, 2003
Date of Patent:
June 9, 2009
Assignee:
Burnham Institute for Medical Research
Inventors:
Erkki Ruoslahti, Kimmo Porkka, Sven Christian
Abstract: A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided.
Abstract: Methods and compositions relating to recombinant anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as a Pseudomonas exotoxin or a detectable label. The invention provides diagnostic methods, and means to inhibit the growth of malignant B cells.
Type:
Grant
Filed:
March 19, 1998
Date of Patent:
June 2, 2009
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
David J. Fitzgerald, Ira Pastan, Elizabeth Mansfield, Robert Kreitman
Abstract: A hybrid polypeptide composed of a p53 epitope peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that includes segments of DNA coding for the epitope peptide and the desired functional protein. An optional linking portion is contemplated. The linking portion of the epitope peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells transformed by the cloning vector is removed therefrom and purified by affinity chromatography techniques by use of an immobilized antibody specific to the antigenic portion of the epitope peptide. The protein is then cleaved from the isolated hybrid polypeptide with an appropriate proteolic enzyme or chemical agent, thereby releasing the mature functional protein in highly purified, highly active state.
Type:
Grant
Filed:
January 10, 2003
Date of Patent:
May 19, 2009
Assignee:
Ambergen, Inc.
Inventors:
Kenneth J. Rothschild, Sadanand Gite, Jerzy Olejnik, Mark Lim
Abstract: A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.
Type:
Grant
Filed:
November 22, 2004
Date of Patent:
May 19, 2009
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Bao-Zhu Yuan, Snorri S. Thorgeirsson, Nicholas Popescu
Abstract: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDII4) and blocks hDII4 binding to a Notch receptor. The human anti-hDII4 antibody or antibody fragment binds dimeric hDII4 with an affinity of 75 pM or better, as measured by surface plasmon resonance.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
May 19, 2009
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and polynucleotide sequences encoding the NMPs, and particularly, those of BLCA-1, and antibodies thereto.
Abstract: The present provides nuclear localization signaling (NLS) sequences derived from titin, comprised of amino acids 181-220: SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR and fragments thereof, such as amino acids 193-208: VQGEEEVP AKKTKTIV; amino acids 199-208: VPAKKTKTIV; and amino acids 200-206: PAKKTKT. The NLS sequences can be linked to agents, such as peptides, proteins or nucleotides, for transporting the agents into the nucleus of cells, and the NLS-agent complex can be further linked to antibodies or ligands for specific binding to cells. Also provided is a method for constructing cDNAs comprising combining a NLS sequence with a nucleic acid sequence for a target protein for expression and entry of the target protein into the nucleus of cells, which then can perform specific functions therein.
Abstract: The invention relates to the use of a preparation based on an antibody directed against a tumor-associated glycosylation for preparing a medicament for the prophylactic and/or therapeutic treatment for the reduction or inhibition, respectively, of the growth of tumor cells in a cancer patient, as well as to a pharmaceutical preparation containing an antibody directed against a tumor-associated glycosylation. Moreover, the invention relates to a preparation for pharmaceutical and/or diagnostic use, a diagnostic method and an agent for determining the risk of metastasis formation in a cancer patient, as well as a method of producing a preparation based on a body fluid or tissue, in each case using the antibody directed against a tumor-associated glycosylation.
Abstract: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.
Type:
Grant
Filed:
June 19, 2003
Date of Patent:
May 5, 2009
Assignee:
Raven biotechnologies, inc.
Inventors:
Jennie P. Mather, Ronghao Li, Zhuangyu Pan, Penelope E. Roberts
Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
Type:
Grant
Filed:
June 14, 2002
Date of Patent:
April 21, 2009
Assignee:
The Regents of the University of California
Inventors:
Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
Type:
Grant
Filed:
September 22, 2005
Date of Patent:
April 21, 2009
Assignee:
Genetech Inc.
Inventors:
Charles W. Eigenbrot, Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
Abstract: The present invention relates to a multivalent Fv antibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fv antibody construct and a method of producing the Fv antibody constructs as well as their use.
Type:
Grant
Filed:
October 10, 2006
Date of Patent:
March 24, 2009
Assignee:
Deutsches Krehsforschungszentrum Stiftung des Offentlichen Rechts
Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.
Type:
Grant
Filed:
May 8, 2003
Date of Patent:
March 24, 2009
Assignees:
Rappaport Family Institute for Research in the Medical Sciences, Rockefeller Institute
Inventors:
Hermann Steller, Hyung Don Ryoo, Aaron Ciechanover, Hedva Gonen
Abstract: Provided for are three novel isoenzyme variants of the human Hyaluronan Synthase gene, HAS1Va, HAS1Vb, and HAS1Vc. Also provided is a method for assessing disease, or susceptibility to disease, in a patient; in which a cell or sample of a cell population is mixed with at least one compound which specifically binds to HAS1Va, HAS1Vb, HAS1Vc or HAS2 isoenzyme or isoenzyme variant genomic mRNA transcript or products arising therefrom; and methods of treatment.
Type:
Grant
Filed:
September 25, 2003
Date of Patent:
March 17, 2009
Assignee:
Governors of the University of Alberta
Inventors:
Linda Pilarski, Sophia Adamia, Andrew Belch, Tony Reiman, Mary Hay
Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies, and antibody binding fragments thereof, capable of being used for therapeutic, diagnostic, detection and cell purification purposes. An exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to surface antigen expressed on multiple myeloma cells and on ovarian cancer cells.
Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.
Type:
Grant
Filed:
August 3, 2004
Date of Patent:
March 3, 2009
Assignees:
Amgen Fremont Inc., Pfizer Inc,
Inventors:
Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia
Abstract: The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.